MX2022001065A - Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. - Google Patents
Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.Info
- Publication number
- MX2022001065A MX2022001065A MX2022001065A MX2022001065A MX2022001065A MX 2022001065 A MX2022001065 A MX 2022001065A MX 2022001065 A MX2022001065 A MX 2022001065A MX 2022001065 A MX2022001065 A MX 2022001065A MX 2022001065 A MX2022001065 A MX 2022001065A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding fragment
- bcma antibody
- antibody
- bcma
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
Abstract
Se proporcionan un anticuerpo anti-BCMA, un fragmento de unión al antígeno del mismo y un uso médico del mismo. Se proporcionan además un anticuerpo quimérico y un anticuerpo humanizado que contiene una región CDR del anticuerpo anti-BCMA, una composición farmacéutica que contiene el anticuerpo anti-BCMA o el fragmento de unión al antígeno del mismo, y el uso de los mismos como un fármaco contra el cáncer y para el tratamiento de enfermedades autoinmunes. En particular, se proporcionan un anticuerpo anti-BCMA humanizado y el uso del mismo en la preparación de un fármaco para tratar enfermedades o afecciones mediadas por BCMA y el uso del mismo en la detección y el diagnóstico de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910695597 | 2019-07-30 | ||
PCT/CN2020/105408 WO2021018168A1 (zh) | 2019-07-30 | 2020-07-29 | 抗bcma抗体、其抗原结合片段及其医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001065A true MX2022001065A (es) | 2022-02-14 |
Family
ID=74228217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001065A MX2022001065A (es) | 2019-07-30 | 2020-07-29 | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220251228A1 (es) |
EP (1) | EP4006055A4 (es) |
JP (1) | JP2022542088A (es) |
KR (1) | KR20220068984A (es) |
CN (1) | CN112585168B (es) |
AU (1) | AU2020322588A1 (es) |
BR (1) | BR112022001546A2 (es) |
CA (1) | CA3146394A1 (es) |
MX (1) | MX2022001065A (es) |
WO (1) | WO2021018168A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230142530A (ko) * | 2021-01-29 | 2023-10-11 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 항체-약물 접합체 및 이의 의학적 용도 |
WO2023098846A1 (zh) * | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
KR101192496B1 (ko) | 2003-11-06 | 2012-10-18 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
PL2406284T3 (pl) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Przeciwciała anty-bcma |
RS64791B1 (sr) | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - vezujući proteini |
UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
NZ725701A (en) * | 2014-04-30 | 2023-09-29 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
HUE053995T2 (hu) * | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | B-sejt-érési antigént célzó antitestek és alkalmazási eljárások |
TWI703157B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Cd3特異性抗體、治療性雙特異性抗體及其用途 |
EA036975B1 (ru) * | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
ES2814550T3 (es) * | 2015-08-17 | 2021-03-29 | Janssen Pharmaceutica Nv | Anticuerpos anti-BCMA, moléculas que se unen a antígeno biespecífico que se unen a BCMA y CD3, y usos de los mismos |
WO2017083511A1 (en) * | 2015-11-13 | 2017-05-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-bcma polypeptides and proteins |
AU2017219747B2 (en) * | 2016-02-17 | 2023-09-28 | Seagen Inc. | BCMA antibodies and use of same to treat cancer and immunological disorders |
CN108341872B (zh) * | 2017-01-23 | 2020-05-19 | 科济生物医药(上海)有限公司 | 靶向bcma的抗体及其应用 |
JP7150820B2 (ja) * | 2017-08-01 | 2022-10-11 | メディミューン,エルエルシー | Bcmaモノクローナル抗体薬剤コンジュゲート |
SG11202003501XA (en) * | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
CN109293772B (zh) * | 2018-09-25 | 2020-09-29 | 上海邦耀生物科技有限公司 | 靶向bcma蛋白的抗体、嵌合抗原受体和药物 |
CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
WO2021190564A1 (zh) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
-
2020
- 2020-07-29 JP JP2022504507A patent/JP2022542088A/ja active Pending
- 2020-07-29 EP EP20848624.1A patent/EP4006055A4/en active Pending
- 2020-07-29 US US17/597,514 patent/US20220251228A1/en active Pending
- 2020-07-29 BR BR112022001546A patent/BR112022001546A2/pt unknown
- 2020-07-29 MX MX2022001065A patent/MX2022001065A/es unknown
- 2020-07-29 AU AU2020322588A patent/AU2020322588A1/en active Pending
- 2020-07-29 WO PCT/CN2020/105408 patent/WO2021018168A1/zh active Application Filing
- 2020-07-29 CA CA3146394A patent/CA3146394A1/en active Pending
- 2020-07-29 CN CN202080004455.4A patent/CN112585168B/zh active Active
- 2020-07-29 KR KR1020227005610A patent/KR20220068984A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220068984A (ko) | 2022-05-26 |
BR112022001546A2 (pt) | 2022-03-22 |
AU2020322588A1 (en) | 2022-02-03 |
US20220251228A1 (en) | 2022-08-11 |
TW202115118A (zh) | 2021-04-16 |
CN112585168B (zh) | 2022-04-15 |
WO2021018168A1 (zh) | 2021-02-04 |
JP2022542088A (ja) | 2022-09-29 |
CA3146394A1 (en) | 2021-02-04 |
EP4006055A4 (en) | 2023-07-19 |
EP4006055A1 (en) | 2022-06-01 |
CN112585168A (zh) | 2021-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501120A1 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
Giovannoni et al. | Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial | |
JP6637439B2 (ja) | 抗ox40抗体及び使用方法 | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
KR102193045B1 (ko) | 항-cd38 항체 및 레날리도마이드를 포함하는 조성물 | |
MX2021014960A (es) | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. | |
MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
MX2022013163A (es) | Anticuerpo contra nectin-4 y aplicacion del mismo. | |
MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
EA033400B1 (ru) | Антитело против cd3 и его применение | |
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
WO2018140845A3 (en) | Bi-specific antibodies to cd64 and a disease antigen | |
MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
MX2021002531A (es) | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MX2019003779A (es) | Uso médico de un conjugado anticuerpo anti-c-met-fármaco citotóxico. | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. |